Mn Services Vermogensbeheer B.V. Has $50.80 Million Stock Holdings in Stryker Corporation $SYK

Key Points

• Mn Services Vermogensbeheer B.V. increased its holdings in Stryker Corporation by 2.5%, acquiring an additional 3,100 shares, bringing its total to 128,400 shares worth approximately $50.8 million.
• Stryker recently reported Q2 earnings of $3.13 per share, exceeding analyst expectations, with a year-over-year revenue increase of 11.1%.
• The company declared a quarterly dividend of $0.84, with an annualized yield of 0.9%, scheduled for payout on October 31st.

Mn Services Vermogensbeheer B.V. boosted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 2.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 128,400 shares of the medical technology company's stock after buying an additional 3,100 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Stryker were worth $50,799,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of SYK. Brighton Jones LLC increased its stake in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares during the period. Waverly Advisors LLC increased its stake in Stryker by 148.5% during the fourth quarter. Waverly Advisors LLC now owns 4,933 shares of the medical technology company's stock worth $1,776,000 after purchasing an additional 2,948 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Stryker by 14.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,003,006 shares of the medical technology company's stock worth $721,182,000 after purchasing an additional 257,035 shares during the period. Glen Eagle Advisors LLC increased its stake in shares of Stryker by 2.7% during the fourth quarter. Glen Eagle Advisors LLC now owns 6,719 shares of the medical technology company's stock worth $2,419,000 after buying an additional 178 shares during the period. Finally, Ames National Corp purchased a new stake in shares of Stryker during the fourth quarter worth approximately $268,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Down 0.3%

SYK stock traded down $1.23 during midday trading on Friday, hitting $376.61. 1,924,253 shares of the company's stock were exchanged, compared to its average volume of 934,259. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $143.98 billion, a price-to-earnings ratio of 49.88, a price-to-earnings-growth ratio of 2.71 and a beta of 0.93. The firm has a 50 day moving average price of $387.52 and a 200-day moving average price of $379.07.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same period in the previous year, the business earned $2.81 EPS. The business's quarterly revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio is presently 44.50%.

Analyst Ratings Changes

SYK has been the subject of a number of research analyst reports. Rothschild & Co Redburn initiated coverage on Stryker in a report on Thursday. They issued a "neutral" rating and a $420.00 price target for the company. Evercore ISI upped their price target on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Rothschild Redb raised Stryker to a "hold" rating in a report on Thursday. BTIG Research reissued a "buy" rating on shares of Stryker in a report on Monday, July 14th. Finally, Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Fourteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $430.33.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Viju Menon sold 500 shares of the business's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.